S&P 500   3,674.10 (+0.14%)
DOW   30,048.06 (+0.55%)
QQQ   304.54 (+0.23%)
AAPL   122.98 (-0.08%)
MSFT   214.74 (-0.29%)
FB   282.94 (-1.59%)
GOOGL   1,821.94 (-0.17%)
AMZN   3,192.56 (-0.34%)
TSLA   596.70 (+4.90%)
NVDA   537.39 (-0.81%)
BABA   267.59 (+2.40%)
CGC   29.03 (+3.02%)
GE   10.64 (+2.01%)
MU   70.66 (+2.24%)
AMD   92.68 (-1.13%)
T   29.18 (+0.31%)
NIO   46.72 (-2.63%)
F   9.23 (+0.33%)
ACB   11.06 (+1.00%)
NFLX   498.29 (-1.01%)
BA   239.49 (+6.99%)
GILD   60.66 (-0.77%)
DIS   153.21 (-0.26%)
S&P 500   3,674.10 (+0.14%)
DOW   30,048.06 (+0.55%)
QQQ   304.54 (+0.23%)
AAPL   122.98 (-0.08%)
MSFT   214.74 (-0.29%)
FB   282.94 (-1.59%)
GOOGL   1,821.94 (-0.17%)
AMZN   3,192.56 (-0.34%)
TSLA   596.70 (+4.90%)
NVDA   537.39 (-0.81%)
BABA   267.59 (+2.40%)
CGC   29.03 (+3.02%)
GE   10.64 (+2.01%)
MU   70.66 (+2.24%)
AMD   92.68 (-1.13%)
T   29.18 (+0.31%)
NIO   46.72 (-2.63%)
F   9.23 (+0.33%)
ACB   11.06 (+1.00%)
NFLX   498.29 (-1.01%)
BA   239.49 (+6.99%)
GILD   60.66 (-0.77%)
DIS   153.21 (-0.26%)
S&P 500   3,674.10 (+0.14%)
DOW   30,048.06 (+0.55%)
QQQ   304.54 (+0.23%)
AAPL   122.98 (-0.08%)
MSFT   214.74 (-0.29%)
FB   282.94 (-1.59%)
GOOGL   1,821.94 (-0.17%)
AMZN   3,192.56 (-0.34%)
TSLA   596.70 (+4.90%)
NVDA   537.39 (-0.81%)
BABA   267.59 (+2.40%)
CGC   29.03 (+3.02%)
GE   10.64 (+2.01%)
MU   70.66 (+2.24%)
AMD   92.68 (-1.13%)
T   29.18 (+0.31%)
NIO   46.72 (-2.63%)
F   9.23 (+0.33%)
ACB   11.06 (+1.00%)
NFLX   498.29 (-1.01%)
BA   239.49 (+6.99%)
GILD   60.66 (-0.77%)
DIS   153.21 (-0.26%)
S&P 500   3,674.10 (+0.14%)
DOW   30,048.06 (+0.55%)
QQQ   304.54 (+0.23%)
AAPL   122.98 (-0.08%)
MSFT   214.74 (-0.29%)
FB   282.94 (-1.59%)
GOOGL   1,821.94 (-0.17%)
AMZN   3,192.56 (-0.34%)
TSLA   596.70 (+4.90%)
NVDA   537.39 (-0.81%)
BABA   267.59 (+2.40%)
CGC   29.03 (+3.02%)
GE   10.64 (+2.01%)
MU   70.66 (+2.24%)
AMD   92.68 (-1.13%)
T   29.18 (+0.31%)
NIO   46.72 (-2.63%)
F   9.23 (+0.33%)
ACB   11.06 (+1.00%)
NFLX   498.29 (-1.01%)
BA   239.49 (+6.99%)
GILD   60.66 (-0.77%)
DIS   153.21 (-0.26%)
Log in
NASDAQ:QDEL

Quidel Stock Forecast, Price & News

$199.91
+0.93 (+0.47 %)
(As of 12/3/2020 02:39 PM ET)
Add
Compare
Today's Range
$195.27
Now: $199.91
$202.04
50-Day Range
$174.44
MA: $230.04
$283.45
52-Week Range
$67.06
Now: $199.91
$306.72
Volume20,816 shs
Average Volume964,150 shs
Market Capitalization$8.41 billion
P/E Ratio56.00
Dividend YieldN/A
Beta0.84
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a point-of-care products for the detection of infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, the company offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, it provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers AmpliVue hand-held molecular diagnostic assay platform for the detection of the pathogen; Solana, an amplification and detection system; and Lyra molecular real-time polymerase chain reaction assays. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, leading universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.
Quidel logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.45 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:QDEL
CUSIP74838J10
Phone858-552-1100
Employees1,250

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$534.89 million
Cash Flow$3.33 per share
Book Value$13.44 per share

Profitability

Net Income$72.92 million

Miscellaneous

Market Cap$8.41 billion
Next Earnings Date2/10/2021 (Estimated)
OptionableOptionable
$199.91
+0.93 (+0.47 %)
(As of 12/3/2020 02:39 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive QDEL News and Ratings via Email

Sign-up to receive the latest news and ratings for QDEL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Quidel (NASDAQ:QDEL) Frequently Asked Questions

How has Quidel's stock been impacted by COVID-19?

Quidel's stock was trading at $89.68 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, QDEL stock has increased by 121.6% and is now trading at $198.69.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Quidel?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quidel in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Quidel
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Quidel?

Wall Street analysts have given Quidel a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Quidel wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Quidel's next earnings date?

Quidel is scheduled to release its next quarterly earnings announcement on Wednesday, February 10th 2021.
View our earnings forecast for Quidel
.

How were Quidel's earnings last quarter?

Quidel Co. (NASDAQ:QDEL) issued its quarterly earnings results on Thursday, October, 29th. The company reported $5.78 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $4.31 by $1.47. The firm earned $476.10 million during the quarter, compared to analyst estimates of $445.30 million. Quidel had a return on equity of 33.86% and a net margin of 23.61%. The firm's quarterly revenue was up 276.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.70 EPS.
View Quidel's earnings history
.

What guidance has Quidel issued on next quarter's earnings?

Quidel issued an update on its third quarter 2020 Pre-Market earnings guidance on Thursday, October, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $475-477 million, compared to the consensus revenue estimate of $394.28 million.

What price target have analysts set for QDEL?

5 analysts have issued 12 month price objectives for Quidel's shares. Their forecasts range from $90.00 to $363.00. On average, they anticipate Quidel's share price to reach $219.00 in the next year. This suggests a possible upside of 10.2% from the stock's current price.
View analysts' price targets for Quidel
.

Who are some of Quidel's key competitors?

What other stocks do shareholders of Quidel own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quidel investors own include NVIDIA (NVDA), DocuSign (DOCU), Tesla (TSLA), PayPal (PYPL), Shopify (SHOP), Square (SQ), Teladoc Health (TDOC), Netflix (NFLX), Advanced Micro Devices (AMD) and Zoom Video Communications (ZM).

Who are Quidel's key executives?

Quidel's management team includes the following people:
  • Mr. Douglas C. Bryant, Pres, CEO & Director (Age 62, Pay $1.07M)
  • Mr. Randall J. Steward, Chief Financial Officer (Age 66, Pay $580.51k)
  • Mr. Robert J. Bujarski, Chief Operating Officer (Age 52, Pay $567.24k)
  • Mr. Ratan S. Borkar, Sr. VP of International Commercial Operations (Age 46, Pay $525.98k)
  • Dr. Werner Kroll, Sr. VP of R&D (Age 63, Pay $566.11k)
  • Ruben Argueta, Director of Investor Relations
  • Mr. Michael Donald Abney Jr., Sr. VP of North American Sales & Distribution (Age 56)
  • Mr. Edward Keith Russell, Sr. VP of Bus. Devel. (Age 52)
  • Ms. Karen Gibson, Sr. VP of Information Systems & Bus. Transformation (Age 58)
  • Mr. William J. Ferenczy, Sr. VP of Cardiometabolic Bus. Unit (Age 64)

What is Quidel's stock symbol?

Quidel trades on the NASDAQ under the ticker symbol "QDEL."

Who are Quidel's major shareholders?

Quidel's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.11%), State Street Corp (2.16%), ArrowMark Colorado Holdings LLC (2.01%), Cannell Peter B & Co. Inc. (1.09%), Arrowstreet Capital Limited Partnership (1.03%) and New York State Common Retirement Fund (0.92%). Company insiders that own Quidel stock include Charles P Slacik, Douglas C Bryant, Edward Keith Russell, Edward L Michael, Karen Gibson, Kenneth F Buechler, Mary Lake Ph D Polan, Matthew Strobeck, Michael Donald Jr Abney, Randall J Steward, Ratan S Borkar, Robert Joseph Bujarski, Thomas D Brown and Werner Kroll.
View institutional ownership trends for Quidel
.

Which institutional investors are selling Quidel stock?

QDEL stock was sold by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, BlackRock Inc., New York State Common Retirement Fund, Paloma Partners Management Co, Cannell Peter B & Co. Inc., Massachusetts Financial Services Co. MA, Gabelli Funds LLC, and Gamco Investors INC. ET AL. Company insiders that have sold Quidel company stock in the last year include Edward Keith Russell, Mary Lake Ph D Polan, Michael Donald Jr Abney, Randall J Steward, Ratan S Borkar, Robert Joseph Bujarski, and Werner Kroll.
View insider buying and selling activity for Quidel
.

Which institutional investors are buying Quidel stock?

QDEL stock was acquired by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, Thrivent Financial for Lutherans, Blair William & Co. IL, C WorldWide Group Holding A S, Point72 Asset Management L.P., AXA S.A., GW&K Investment Management LLC, and First Trust Advisors LP. Company insiders that have bought Quidel stock in the last two years include Douglas C Bryant, Edward L Michael, and Matthew Strobeck.
View insider buying and selling activity for Quidel
.

How do I buy shares of Quidel?

Shares of QDEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Quidel's stock price today?

One share of QDEL stock can currently be purchased for approximately $198.69.

How big of a company is Quidel?

Quidel has a market capitalization of $8.36 billion and generates $534.89 million in revenue each year. The company earns $72.92 million in net income (profit) each year or $2.73 on an earnings per share basis. Quidel employs 1,250 workers across the globe.

What is Quidel's official website?

The official website for Quidel is www.quidel.com.

How can I contact Quidel?

Quidel's mailing address is 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA, 92121. The company can be reached via phone at 858-552-1100 or via email at [email protected]

This page was last updated on 12/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.